Associates in Ophthalmology — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$7,068	2
2022	Research	$82	1
2021	Research	$7,282	1
2020	Research	$7,908	5
2019	Research	$2,050	5

Breakdown

Who paid Research payments · program years 2019–2023

Allergan Inc. $9,831 9 payments
Novartis Pharmaceuticals Corporation $7,492 3 payments
Astellas Pharma Global Development $7,068 2 payments

Studies the money was for Research payments · program years 2019–2023

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $7,851 4 payments
A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $7,492 3 payments
An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2) $7,068 2 payments
Efficacy and Safety of Bimatoprost Sustained-Release Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension $990 2 payments
A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related MacUlar Degeneration $900 2 payments
Efficacy and Safety of Bimatoprost Sustained-Release (Sr) in Patients With Open-Angle Glaucoma Or Ocular Hypertension $90 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.